Consultation on clinical commissioning policies: Levofloxacin nebuliser solution

Closed 16 Jul 2017

Opened 16 Jun 2017

Overview

NHS England has today (16th June 2017) launched a 30 day public consultation on a clinical commissioning policy for Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (Adults). 

Cystic fibrosis (CF) is the most common, life-limiting disease in the UK. Inhaled antibiotics are a normal treatment for people with cystic fibrosis with chronic lung infection. Inhaled levofloxacin is a new antibiotic to provide an extra option for treatment.

There has already been extensive engagement on this policy, it has been developed with the support and input of lead clinicians and patient and public representatives. This approach has helped ensure that the views of key stakeholders have informed and influenced the development of this policy to date. We now wish to test it further with wider groups of stakeholders.

Related documents

Clinical Commissioning Policies

Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (Adults):

Audiences

  • GPs
  • Nurses
  • Health visitors
  • Clinicians
  • Managers
  • Commissioners
  • Directors of public health
  • Pharmacists
  • Doctors
  • Midwives
  • Health care assistants
  • Healthcare scientists
  • Paramedics
  • Chiropodists/podiatrists
  • Dietitians
  • Occupation therapists
  • Orthotists
  • Orthopists
  • Prosthesists
  • Physiotherapists
  • Diagnostic radiographers
  • Therapeutic radiographers
  • Speech and language therapists
  • Childcare providers
  • Allied health professionals
  • Care-givers
  • Ophthalmic practitioners
  • Responsible officers
  • Clinical psychologists
  • Paediatric neuropsychologists
  • GP Practices
  • Clinical Nurse Specialist
  • Practice managers
  • Receptionists
  • Dental surgeons
  • Neonatal and maternity staff
  • Foundation trusts
  • Mental health trusts
  • Community healthcare trusts
  • Tribunal service
  • Clinical commissioning groups (CCGs)
  • Commissioning support units (CSUs)
  • Strategic clinical networks (SCNs)
  • GP Practices
  • Primary care
  • Care Quality Commission
  • Health Education England
  • Health Protection Agency
  • Local Government Association
  • Monitor
  • National Institute for Health and Care Excellence
  • Health and Wellbeing boards
  • Healthwatch (national and local)
  • Health and Social Care Information Centre
  • NHS Trust Development Authority
  • Local Involvement Networks
  • NHS England Partnership Organisations
  • National directors
  • Regional directors
  • Area Team directors
  • All NHS England Staff
  • All P&I staff
  • Policy leads
  • Voluntary groups
  • Community groups
  • Charities
  • Advocacy or support organisations
  • DH third sector strategic partners
  • Regulatory bodies
  • Academic/professional institutions
  • Employer representatives
  • Employee representatives
  • Trade unions
  • Deaneries
  • Higher education institutions
  • Royal Colleges
  • Service providers
  • All interested stakeholders
  • Pharmaceutical Industry
  • Local authorities
  • Social care providers
  • Patients
  • Carers
  • Service users
  • Retailers
  • Suppliers
  • Information providers
  • Information professionals
  • Informatics professionals

Interests

  • Specialised commissioning